Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.24.1.u1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Service Line
Revenue by Service Line
Three Months Ended March 31,
(in thousands) 2024 2023
Biologics and drug delivery
Disposable products $ 553  $ 594 
Services and license fees 3,754  2,082 
Subtotal – Biologics and drug delivery revenue 4,307  2,676 
Functional neurosurgery navigation and therapy
Disposable products 1,927  1,858 
Services —  503 
Subtotal – Functional neurosurgery navigation and therapy
 1,927  2,361 
Capital equipment and software
Systems and software products 1,155  178 
Services 250  218 
Subtotal – Capital equipment and software revenue 1,405  396 
Total revenue $ 7,639  $ 5,433 
Schedule of Other Current Assets
March 31, 2024 December 31, 2023
(in thousands)
Accounts receivable, net $ 2,511  $ 3,211 
Other contract assets
Unbilled receivables $ 612  $ 733 
Deferred contract costs $ 193  $ — 
Schedule of Revenue Recognized by Contract Liability The unearned portion of all such fees is classified as deferred revenue.
March 31, 2024 December 31, 2023
(in thousands)
Deferred revenues $ 1,690  $ 3,154